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Introduction
The observation that serotonin is involved in migraine led to
the development of drugs acting on the serotonergic recep-
tors. Historically, ergot derivatives were the first class of drug
acting on a series of receptors, namely, dopaminergic, adren-
ergic, and serotonergic; triptans were a novel class of drugs
acting as selective agonists of 5-HT 1B/1D receptors [1, 2].
Since the introduction in 1983 of the first triptan, suma-
triptan, research has led to the development of the so-
called second-generation triptans: zolmitriptan, naratrip-
tan, rizatriptan, almotriptan, eletriptan, and frovatriptan.
One of the most frequently asked question is “Which is
the best triptan?” It is difficult to find an answer, because the
significance of “best” depends on the features that would
serve to discriminate the triptans (i.e., pharmacokinetics,
efficacy, potency, safety, rapidity of action, etc.). Moreover,
it is difficult to predict the patient’s clinical response to a
given triptan, and in addition the patient’s preference is a
complex parameter that depends on unique and individual
factors typical to that subject. In conclusion, the answer
depends on the point of view that we are taking.
The pharmaceutical formulation remains an important
parameter for the evaluation of overall efficacy. Injectable
sumatriptan is the most rapidly and potently effective trip-
tan: after 10 min it provides headache relief (major relief
compared with placebo) and by 2 h headache relief is report-
ed by 80% of patients; it also acts on migraine-associated
symptoms.
Intranasal administration provides significant relief
within 40–60 min, and seems to be useful even in the treat-
ment of short headaches such as cluster headache [3–7].
Several oral triptans can provide headache relief
within 60–120 min; however, in the case of intense pain
that tends to increase quickly in which nausea and vom-
iting are associated subcutaneous injection or a nasal
spray formulation are more appropriate. Almotriptan
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and naratriptan show a lower incidence of side effects,
in particular chest and central nervous system symp-
toms [8].
Pharmacokinetics of triptans
Table 1 presents the pharmacokinetic parameters of trip-
tans. Sumatriptan shows a low oral bioavailability (14%),
a short elimination half-life, and a modest time to maxi-
mal serum concentration. This is the basis for the devel-
opment of drugs with different pharmacokinetic and inter-
action profiles.
Zolmitriptan, naratriptan, rizatriptan, and frovatriptan
show gender differences in their pharmacokinetics,
whereas with almotriptan there are no differences between
men and women, but the pharmacokinetic profile is affect-
ed by age. These differences are not considered clinically
relevant, but in patients with severe hepatic impairment, a
reduction of the dose may be necessary, in particular when
using zolmitriptan.
Almotriptan plasma concentration levels are increased
by 37% by co-administration of moclobemide and vera-
pamil. Sumatriptan does not interact with propranolol,
alcohol, or paroxetine, but plasma levels are significantly
increased by moclobemide.
The half-life of zolmitriptan is prolonged by 32%
when co-administered with propanolol; moreover,
moclobemide increases the area under the curve (AUC)
and the active metabolites of this triptan.
Plasma concentration levels of rizatriptan are
increased by 70% by propranolol, and it is therefore
advisable to maintain the lower dose of 5 mg.
Moclobemide augments rizatriptan plasma concentration,
and the co-administration with any monoamine oxidase
type A inhibitor is contraindicated. The metabolic interac-
tions of triptans are summarized in Table 2 [9].
Efficacy
Pharmacokinetic differences among the new triptans are not
related to clinical efficacy. Table 3 reports the main parame-
ters used to evaluate the efficacy and safety of triptans.
The oral triptans share the same ability to provide pain
relief within 30–60 min. Concerning the reduction of
Table 1 Pharmacokinetic profiles of triptans (AUC, area under the curve)
Triptan Tmax (h) Oral bioavailability (%) T1/2 (h) AUC (mg/l h) Active metabolites
Sumatriptan 50 mg 2 14 2 118 No
Sumatriptan 100 mg 1.5 14 2 158 No
Rizatriptan 5 mg 1.2 38 1.4 17.4 Yes
Rizatriptan 10 mg 1 40 2 50 Yes
Zolmitriptan 2.5 mg 2 46 2.6 17 Yes
Naratriptan 2.5 mg 2 74 5.5 98 No
Naratriptan 5 mg 2 68 5.3 200 No
Naratriptan 10 mg 1.5 68 5.5 387 No
Eletriptan 40 mg 1.8 50 5.3 670 Yes
Eletriptan 80 mg 1.4 50 6.3 1,661 Yes
Frovatriptan 2.5 mg 3 29.6 25.7 94 No
Frovatriptan 40 mg 5 17.5 29.7 881 No
Almotriptan 12.5 mg 2.5 49.5 3.1 80 No
Almotriptan 25 mg 1.5 69 3.19 558.5 No
Table 2 Metabolic interactions of triptans
Almotriptan Eletriptan Frovatriptan Naratriptan Rizatriptan Sumatriptan Zolmitriptan
Renal No Yes No No Yes No No
Hepatic No No No No Yes Yes Yes
MAOI No No No No Yes Yes Yes
SSRI No No No No No Yes No
CYP3A4 inhibitors No Yes No No No Yes No
Active metabolites No Yes No No Yes No Yes
Propranolol No No No No Yes No No
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headache recurrence, the rates are similar for rizatriptan,
zolmitriptan, and sumatriptan; however, with naratriptan
the rates of recurrence were low in some studies versus
placebo, and significantly lower in comparison with
sumatriptan in a double-blind crossover study involving
patients with a high percentage of recurrence.
Frovatriptan has the longest half-life and shows a
lower rate of headache recurrence.
The intrapatient consistency (percentage of crisis
treated successfully in an individual patient) rather than
the population consistency (percentage of patients
responding to consecutive attacks) is the most appropriate
method of evaluating the consistency of a drug.
Studies with oral sumatriptan show that 64% of
patients achieve pain relief in at least two of three attacks
and 33% had pain relief in all three crises.
Almotriptan, the triptan with the highest bioavailabili-
ty (70%), provided pain relief in at least two attacks in
75% of patients treated with 12.5 mg, and almost 50% of
these patients were pain-free in all three attacks. These
data suggest a possible relationship between oral avail-
ability and consistency of response. On the other hand,
intrapatient response consistency with rizatriptan
(bioavailability of 40%) was higher than for almotriptan:
pain relief in 86% at 2 h for two of three attacks [9].
Safety
The most frequently reported adverse events are dizzi-
ness/vertigo, somnolence, nausea/vomiting, asthenia, dry
mouth, chest symptoms, and paresthesias. The tolerability
profiles of rizatriptan, sumatriptan, zolmitriptan, and
eletriptan are similar.
The incidence of new adverse events is lower with
naratriptan, frovatriptan, and almotriptan: the tolerability
profile of almotriptan 12.5 mg is similar to placebo.
Almotriptan and naratriptan show a low incidence of
chest symptoms: 0.1%–0.2% and 1%, respectively.
Although the potential for any triptan to cause con-
striction of the coronary arteries is very low at a therapeu-
tic dosage, these drugs are contraindicated in patients who
have coronary artery disease [10–12].
Table 3 Clinical efficacy and safety parameters of triptans
Efficacy parameters Safety parameters
Therapeutic gain = response rate in treated subjects/response rate Absolute risk increase = adverse effects (AEs) rate in treated 
in control group subjects/AEs rate in control group
Relative benefit increase = therapeutic gain/response rate Relative risk increase = absolute risk increase/AEs rate in control
in control group group
Number needed to treat = 100/therapeutic gain (NNT) Number needed to harm = 100/absolute risk increase (NNH)
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